Todd A. Huffman
Fundador en Padlock Therapeutics, Inc. .
Cargos activos de Todd A. Huffman
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Director/Miembro de la Junta | 01/01/2014 | - |
| Fundador | 01/01/2014 | - | |
| The University of Virginia School of Medicine | Corporate Officer/Principal | - | - |
Historial de carrera de Todd A. Huffman
Antiguos cargos conocidos de Todd A. Huffman.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Analista de Capital Privado | 01/01/2007 | 30/03/2010 |
Formación de Todd A. Huffman.
| University of Virginia | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
| 2 |
Operativa
| Private Equity Analyst | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectorial
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
RCT BioVentures
RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Finance |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Todd A. Huffman
- Experiencia
